Chairman of medmix Board of Director, Gregoire Poux-Guillaume to take on an external CEO mandate, will not stand for re-election as Chairman at AGM 2023
June 28, 2022
Ad hoc announcement pursuant to Art. 53 LR
AkzoNobel announced today that Gregoire Poux-Guillaume will become the company’s new Chief Executive Officer (CEO) as of November 1, 2022. While he currently seeks to keep a board seat at medmix beyond the Annual General Meeting (AGM) in 2023, Mr. Poux-Guillaume has informed the Board of Directors that he will not stand for re-election as Chairman, to comply with governance best practices. The Board of Directors will inform on the Chairperson succession plan in due time.
medmix is a global leader in high-precision delivery devices. We occupy leading positions in the healthcare, consumer and industrial end-markets. Our customers benefit from a dedication to innovation and technological advancement that has resulted in over 900 active patents. Our 13 production sites worldwide together with our highly motivated and experienced team of 1’900 employees provide our customers with uncompromising quality, proximity and agility. medmix is currently headquartered in Baar, Switzerland. Our shares are traded on the SIX Swiss Exchange (SIX: MEDX). www.medmix.swiss
Media Relations: Domenico Truncellito, Head External Communications
Investor Relations: Christoph Ladner, Head of Investor Relations
This document may contain forward-looking statements including, but not limited to, projections of financial developments, market activity, or future performance of products and solutions containing risks and uncertainties. These forward-looking statements are subject to change based on known or unknown risks and various other factors that could cause actual results or performance to differ materially from the statements made herein.